Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD)
- 438 Downloads
Experimental studies suggest a detrimental role for cyclic adenosine monophosphate (cAMP) and vasopressin in the pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). It is unknown, however, whether urinary cAMP and copeptin concentration are associated with disease severity in patients with ADPKD.
Urinary cAMP (u-cAMP) and copeptin concentration (u-copeptin) were measured by immunoassay in ADPKD patients with CKD stage ≤4. We compared our measurements with clinical parameters including estimated glomerular filtration rate (eGFR), total kidney volume (TKV), and height-adjusted TKV (htTKV). Logarithmic transformation of all variables was performed to fulfill the requirement of equal distribution of the residuals.
We included 50 patients in this study (24 females and 26 males; mean age: 49.3 years). The median eGFR and TKV were 53.2 ml/min/1.73 m2 (interquartile range: IQR; 29.4–68.45) and 1138.1 ml (IQR; 814.7–2065.0), respectively. The median u-copeptin level was 12.19 (IQR; 6.91–22.32) ng/ml. Although u-cAMP/u-Cr was not significantly correlated with TKV (R = −0.006, p = 0.967) and eGFR (R = 0.077, p = 0.602), urinary copeptin/u-Cr was statistically associated with the various markers of disease severity in ADPKD [positively with TKV (R = 0.351, p = 0.014), htTKV (R = 0.383, p = 0.008) and negatively with eGFR (R = −0.304, p = 0.036)].
In ADPKD subjects, a higher u-copeptin is associated with disease progression, suggesting that u-copeptin may be a new surrogate marker to predict renal prognosis in ADPKD.
KeywordsAutosomal dominant polycystic kidney disease Vasopressin Copeptin GFR Total kidney volume Marker
This work was supported in part by a grant for the Progressive Renal Diseases Research Project from the Ministry of Health, Labour and Welfare of Japan.
Conflict of interest
Honoraria: Satoru Muto, Shigeo Horie (Otsuka Pharmaceutical); Subsidies or Donations: Satoru Muto, Haruna Kawano, Shigeo Horie (Otsuka Pharmaceutical); Endowed departments by commercial entities: Shigeo Horie (Otsuka Pharmaceutical); Travel fees, gifts, and others: Satoru Muto, Shigeo Horie (Otsuka Pharmaceutical).
- 10.Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis. 2013;61:420–9.PubMedCentralCrossRefPubMedGoogle Scholar
- 12.Boertien WE, Meijer E, Zittema D, van Dijk MA, Rabelink TJ, Breuning MH, et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2012;27:4131–7.CrossRefPubMedGoogle Scholar
- 13.Zittema D, Berg EV, Meijer E, Boertien WE, Muller Kobold AC, Franssen CFM, et al. kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephol. 2014;9:1533–62.Google Scholar
- 19.R Development Core Team. R. a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2011.Google Scholar
- 29.Littlejohn NK, Siel RB Jr, Ketsawatsomkron P, Pelham CJ, Pearson NA, Hilzendeger AM, et al. Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent. Am J Physiol Regul Integr Comp Physiol. 2013;304:R818–28.PubMedCentralCrossRefPubMedGoogle Scholar